- Home
- BGM
as 09-17-2024 1:30pm EST
Stocks
Qilian International Holding Group Ltd is a pharmaceutical and chemical company. The company is engaged in the development, manufacture, marketing, and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives products, heparin products, sausage casings, and fertilizers. It operates through three segments namely, Oxytetracycline and Licorice products and TCMD; Fertilizer; and Heparin products and Sausage casing. Oxytetracycline and Licorice products and TCMD segment generates majority of the revenue.
| Founded: | 2019 | Country: | China |
| Employees: | N/A | City: | N/A |
| Market Cap: | 45.5M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 28.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.77 - $8.96 | Next Earning Date: | 08-14-2024 |
| Revenue: | $29,870,461 | Revenue Growth: | -51.77% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Compare BGM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BGM QILIAN INTERNATIONAL HLDG GROUP LTD - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.